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Abstract 530 – Table 1. Characteristics of Individual Trials included in Meta-analysis
1st author, year No. patients Mean (SD) age of No. (%) women Mean (SD) BMI of Minimum JSW at baseline
randomized patients randomized randomized patients randomized in patients randomized
to CS/placebo to CS/placebo to CS/placebo to CS/placebo to CS/placebo
Michel, 2005 150/150 62.5 (9.1)/63.1 (10.7) 76 (51)/78 (52) 27.7 (5.2)/28.1 (5.5) 2.41 (0.14)/2.35 (0.14)
Sawitzke, 2008 123/134 (only 71/70 were assessable) 56.4 (9.2)/56.6 (8.4) 51 (72)/45 (64) NS/NS 3.86 (0.90)/4.07 (0.93)
Kahan, 2009 309/313 62.9 (0.5)/61.8 (0.5) 216 (70)/209 (67) 28.5 (0.4)/29.0 (0.4) 3.73 (0.08)/3.81 (0.07)
data from the intention-to-treat populations for pooling. Results
were summarized for both the absolute difference between the
chondroitin sulfate and placebo-treated groups as well as the
standardized effect size using the pooled standard deviations.
Fixed effects models were used as the I2 statistic showed no evi-
dence of between-trial heterogeneity. All analyses were perfomred
using RevMan version 5 software (www.cc-ims.net).
Results: Results from 3 randomized placebo-controlled trials of 2
years duration were included in this pooled analysis; characteris-
tics of the individual trials are shown in the Table. Overall, data
from 530 patients who were randomized to chondroitin sulfate at
a dose of 800 mg/day and 533 patients who were randomized to
placebo were included in the pooled analysis. The pooled mean
difference in decline in minimum tibiofemoral joint space width over
2 years was 0.13 mm (95% conﬁdence intervals [CI] 0.06, 0.19)
less in the chondroitin sulfate treated groups compared to the
placebo treated groups (P = 0.0002). This difference corresponds
to an effect size of 0.23 (95% CI 0.11, 0.35) (P = 0.0002).
Conclusions: These data demonstrate that chondroitin sulfate at
a dose of 800 mg/day is effective for reducing the rate of decline in
minimum medial tibiofemoral joint space width in patients with knee
OA over 2 years. These results support OARSI recommendations
for the use of chondroitin sulfate as a structure-modifying agent
for patients with knee OA.
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Purpose: Long-term use of non steroidal anti-inﬂammatory drugs
(NSAIDs) for the treatment of inﬂammatory conditions such as
osteoarthritis is hampered by gastrointestinal (GI) side effects
and increased potential for cardiovascular events. HCT 1026 is a
cyclooxygenase-inhibiting nitric oxide donator (CINOD) providing
balanced cyclooxygenases inhibition along with the release of nitric
oxide (NO). Through NO donation, HCT 1026 may offer improved
tolerability over traditional NSAIDs, potentially by mitigating the
detrimental effects caused by prostaglandin suppression. The
aim of this study is to characterize the anti-inﬂammatory activity,
gastrointestinal tolerability and in vivo NO release of HCT 1026, a
ﬂurbiprofen-based CINOD, in animal models
Methods: Pleural inﬂammation was induced in anaesthetised
Sprague-Dawley rats by injection of 1% carrageenan into the
thoracic cavity. Animals were euthanized 4h later and thoracic
exudates collected for determination of volume and leukocyte in-
ﬁltration. HCT 1026, ﬂurbiprofen (both at 12.5 and 50 μmol/kg)
or vehicle were administered by gavage 1h prior to carrageenan
injection. GI tolerability was assessed in rats treated twice daily
with vehicle or 40 μmol/kg HCT 1026 or ﬂurbiprofen and sacriﬁced
after 5-7 days for determination of stomach and ileum damage
(presence of ulcers, adhesions and ileum damage score in mm).
In vivo NO donation was tested in New Zealand rabbits previously
anaesthetised, ventilated, and cannulated in the carotid artery for
blood pressure (BP) measurement. Animals were treated with 30
mg/kg L-NAME to quench endogenous NO production and HCT
1026 or ﬂurbiprofen (100 μmol/kg in 6 min, infusion in the jugular
vein) or vehicle (DMSO) were administered following a cross-over
protocol (1 h wash out)
Results: HCT 1026 (12.5 and 50 μmol/kg) dose-dependently in-
hibited carrageenan-induced pleural ﬂuid accumulation (46 and 61
% reduction vs. control, respectively) and neutrophil inﬁltration (22
and 48% reduction vs. control, respectively), similar to equimolar
doses of ﬂurbiprofen.
Administration of 40 μmol/kg HCT 1026 for 7 days was well
tolerated and caused only a slight reduction in haematocrit (8%
decrease vs. vehicle), while administration of an equimolar amount
of ﬂurbiprofen strikingly decreased haematocrit (25% vs. vehicle),
causing death of almost all animals before the end of the study.
Analysis of the GI tract at sacriﬁce revealed no gastric ulcers
in HCT 1026-treated animals, with adhesions in 2 out of 10
animals and minimal ileum damage (0.2±0.1 mm). In contrast,
ﬂurbiprofen caused gastric ulcers in 2 out of 9 animals, adhesions
in all animals, and extensive ileum damage (21.4±3.6 mm).In
rabbits pretreated with L-NAME, infusion of HCT 1026 resulted
in a moderate signiﬁcant increase in exhaled NO (from 0.4±0.15
to 2.3±0.4 ppb) which lasted up to 60 min, and a reduction of
BP of ∼21 cmH2O (15.5 mmHg). Flurbiprofen did not alter these
parameters
Conclusions:HCT 1026 displays effective anti-inﬂammatory prop-
erties comparable to the reference NSAID ﬂurbiprofen in the
pleurisy model, with a superior GI tolerability proﬁle, likely due to
its ability to donate NO (as observed in vivo)
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Purpose: Chronic treatment of osteoarthritis with non steroidal
anti-inﬂammatory drugs (NSAIDs) is associated with several
gastro-intestinal (GI) side effects. In addition, increased cardio-
vascular risk has been documented following their long-term use.
Cyclooxygenase-inhibiting nitric oxide donators (CINODs) bear
both COX-1 and COX-2-inhibiting activity as well as nitric oxide
(NO) donating properties. The rationale behind this approach is
to increase GI tolerability while retaining the anti-inﬂammatory
properties typical of NSAIDs. Here, we present the GI safety pro-
ﬁle of HCT 2037, a ketoprofen-based CINOD, in a rat model of
inﬂammation.
Methods: Efﬁcacy and gastric damage were evaluated in parallel
in the carrageenan-induced model of inﬂammation. Male Wistar
rats were orally administered 0.3-35.7 mg/kg HCT 2037 or equimo-
lar doses of ketoprofen 30 min before carrageenan injection into
the right paw. Edema was measured at regular times for further
5 h. Rats were then euthanized and the stomachs excised and
analyzed to assess gastric damage score (sum in mm of all hem-
orrhagic erosions). UD30 and ED30 were calculated as the doses
